Sixu Liu
Tongzipo Road
Changsha, 410013, China
Changsha, 410013, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Discovery of meisoindigo derivatives as noncovalent and orally available Mpro inhibitors: their therapeutic implications in the treatment of COVID-19.
Journal: European journal of medicinal chemistry
Published: February 16, 2024
A Cullin 5-based complex serves as an essential modulator of ORF9b stability in SARS-CoV-2 replication.
Journal: Signal transduction and targeted therapy
Published: October 29, 2023
Targeting epidermal growth factor receptor signalling pathway: A promising therapeutic option for COVID-19.
Journal: Reviews in medical virology
Published: August 14, 2023
M6A-mediated upregulation of circMDK promotes tumorigenesis and acts as a nanotherapeutic target in hepatocellular carcinoma.
Journal: Molecular cancer
Published: January 28, 2022
Host E3 ligase HUWE1 attenuates the proapoptotic activity of the MERS-CoV accessory protein ORF3 by promoting its ubiquitin-dependent degradation.
Journal: The Journal of biological chemistry
Published: October 07, 2021
Microbiome Profiling Using Shotgun Metagenomic Sequencing Identified Unique Microorganisms in COVID-19 Patients With Altered Gut Microbiota.
Journal: Frontiers in microbiology
Published: May 20, 2021
Epigallocatechin-3-gallate, an active ingredient of Traditional Chinese Medicines, inhibits the 3CLpro activity of SARS-CoV-2.
Journal: International journal of biological macromolecules
Published: November 18, 2020
Showing 1-8 of 8
Last Updated: 09/26/2026